Upstream Bio, Inc. (UPB)

Upstream Bio's stock has shown significant movement in the past six months, increasing by 138.84% due to positive Phase 2 trial results for verekitug in CRSwNP. The company's shares began trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol "UPB". On August 6, 2025, Upstream Bio reported a loss of ($0.74) EPS, missing the consensus estimate; however, revenue for the quarter was $0.94 million, exceeding expectations. The stock's 52-week range has been between $5.14 and $29.46, and as of October 26, 2025, it traded at $21.86.

Demand for Upstream Bio's treatments for inflammatory and respiratory diseases is primarily driven by disease prevalence and treatment efficacy rather than typical consumer demand seasonality. While respiratory conditions can experience seasonal exacerbations, the chronic nature of these diseases results in a consistent need for ongoing treatment. The company's focus on addressing the root causes of inflammation aims to provide durable and comprehensive disease control, suggesting a steady demand for effective therapies year-round.

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, particularly severe respiratory disorders. Founded in 2021 and headquartered in Waltham, Massachusetts, the company is led by CEO E. Rand Sutherland and is centered around the research, development, and potential commercialization of novel therapies. Their lead product candidate, verekitug (UPB-101), is a monoclonal antibody targeting TSLP, a key driver of inflammatory responses. Verekitug is in Phase 2 clinical development for severe asthma and CRSwNP, with plans to initiate a Phase 2 trial for COPD in July 2025. The company aims to provide a differentiated treatment option by targeting inflammation at its source.

Upstream Bio, Inc. is headquartered in Waltham, Massachusetts, United States. While the company aims for global market penetration and participates in international scientific forums, its current clinical trial sites are mainly located across various states in the United States.

Upstream Bio has a "Moderate Buy" consensus recommendation from analysts, with an average one-year price target of $53.33. Analyst firms like Piper Sandler and Truist Financial have given positive ratings, driven by promising Phase 2 trial results for verekitug. However, Weiss Ratings reissued a "sell" rating in September 2025, and the company's removal from some growth-focused indices has been noted as a potential factor affecting its reputation.

Upstream Bio, Inc. has significant institutional ownership, with 89.69% of its shares held by institutional shareholders and 33.42% owned by insiders. Major institutional owners include Fmr Llc, Orbimed Advisors Llc, Altshuler Shaham Ltd, Decheng Capital LLC, TCG Crossover Management, LLC, Enavate Sciences GP, LLC, Bain Capital Life Sciences Investors, LLC, VR Adviser, LLC, Vanguard Group Inc, and BlackRock, Inc. Orbimed Advisors LLC is a significant individual/insider shareholder, owning 5.81 million shares, representing 10.78% of the company. Other institutional investors like Norges Bank, Geode Capital Management LLC, BNP Paribas Financial Markets, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., and The Manufacturers Life Insurance Company have also adjusted their positions in the company.